Trials / Unknown
UnknownNCT04074213
Clozapine and Haematologic Malignancies: Observational and Retrospective Study Using the WHO Pharmacovigilance Database
Clozapine and Haematologic Malignancies: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000,000 (estimated)
- Sponsor
- University Hospital, Caen · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Clozapine may lead to various adverse reactions, including neutropenia and agranulocytosis. This study investigates reports of lymphoma and leukaemias for clozapine in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).
Detailed description
Clozapine is responsible of a wide range of adverse side effects.The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of haematologic malignancies following treatment with clozapine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clozapine | Clozapine treatment |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2024-03-01
- Completion
- 2024-08-01
- First posted
- 2019-08-30
- Last updated
- 2019-08-30
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04074213. Inclusion in this directory is not an endorsement.